Please wait while the formulary information is being retrieved.
PEGINTRON (PEGINTERFERON ALFA-2B)
- Chronic hepatitis C - genotype 1
- Chronic hepatitis C - genotype 3
- Chronic hepatitis C - genotype 4
- Chronic hepatitis C - genotype 2
50 mcg/0.5 mL subcutaneous kit
- Inject 1 mcg/kg by subcutaneous route once weekly
50 mcg/0.5 mL subcutaneous kit
- Inject 1 mcg/kg by subcutaneous route once weekly
Chronic hepatitis C - genotype 1
- Inject 1.5 mcg/kg by subcutaneous route once weekly for 1 year in combination with ribavirin
- Inject 1 mcg/kg by subcutaneous route once weekly for 1 year
- Inject 1 mcg/kg by subcutaneous route once weekly
- Inject 1.5 mcg/kg by subcutaneous route once weekly in combination with ribavirin
Chronic hepatitis C - genotype 2
- Inject 1.5 mcg/kg by subcutaneous route once weekly for 1 year in combination with ribavirin
- Inject 1 mcg/kg by subcutaneous route once weekly for 1 year
- Inject 1 mcg/kg by subcutaneous route once weekly
- Inject 1.5 mcg/kg by subcutaneous route once weekly in combination with ribavirin
Chronic hepatitis C - genotype 3
- Inject 1.5 mcg/kg by subcutaneous route once weekly for 1 year in combination with ribavirin
- Inject 1 mcg/kg by subcutaneous route once weekly for 1 year
- Inject 1 mcg/kg by subcutaneous route once weekly
- Inject 1.5 mcg/kg by subcutaneous route once weekly in combination with ribavirin
Chronic hepatitis C - genotype 4
- Inject 1.5 mcg/kg by subcutaneous route once weekly for 1 year in combination with ribavirin
- Inject 1 mcg/kg by subcutaneous route once weekly for 1 year
- Inject 1 mcg/kg by subcutaneous route once weekly
- Inject 1.5 mcg/kg by subcutaneous route once weekly in combination with ribavirin
Chronic hepatitis C - genotype 5
- Inject 1.5 mcg/kg by subcutaneous route once weekly for 1 year in combination with ribavirin
- Inject 1 mcg/kg by subcutaneous route once weekly for 1 year
- Inject 1 mcg/kg by subcutaneous route once weekly
- Inject 1.5 mcg/kg by subcutaneous route once weekly in combination with ribavirin
Chronic hepatitis C - genotype 6
- Inject 1.5 mcg/kg by subcutaneous route once weekly for 1 year in combination with ribavirin
- Inject 1 mcg/kg by subcutaneous route once weekly for 1 year
- Inject 1 mcg/kg by subcutaneous route once weekly
- Inject 1.5 mcg/kg by subcutaneous route once weekly in combination with ribavirin
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Droxia
- Fazaclo
- Ferriprox
- Hydrea
- hydroxyurea
- Versacloz
Severe
Moderate
- colchicine
- colchicine-probenecid
- Colcrys
- erlotinib
- Tarceva
- Acute pancreatitis
- Autoimmune hepatitis
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hemorrhagic colitis
- Hepatic failure
- Ischemic colitis
- Sickle cell disease
- Thalassemia
- Ulcerative colitis
Contraindicated
- Acute myocardial infarction
- Aplastic anemia
- Autoimmune disease
- Bipolar disorder
- Cardiac arrhythmia
- Cerebrovascular accident
- Depression
- Diabetic retinopathy
- Drug dependence
- Hepatic cirrhosis
- Homicidal ideation
- Hypertensive retinopathy
- Hyperthyroidism
- Hypothyroidism
- Kidney disease with reduction in GFR
- Manic disorder
- Papilledema
- Psychotic disorder
- Pulmonary infiltrates
- Recipient of organ transplant
- Severe anemia
- Severe infection
- Severe neutropenic disorder
- Severe thrombocytopenia
- Suicidal ideation
Severe
Moderate
- Anemia
- Diabetes mellitus
- Hypertriglyceridemia
- Kidney disease with likely reduction in GFR
- Periodontitis
- Pulmonary disease
PEGINTRON (PEGINTERFERON ALFA-2B)
- Chronic hepatitis C - genotype 1
- Chronic hepatitis C - genotype 3
- Chronic hepatitis C - genotype 4
- Chronic hepatitis C - genotype 2
- Abnormal hepatic function tests
- Depression
- Irritability
- Mood changes
- Alopecia
- Anorexia
- Arthralgias
- Chills
- Diarrhea
- Dizziness
- Dysgeusia
- Exfoliative dermatitis
- Fatigue
- Fever
- Flu-like symptoms
- Headache disorder
- Injection site sequelae
- Myalgias
- Nausea
- Paresthesia
- Parosmia
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Anemia
- Dyspnea
- Hypothyroidism
- Peripheral neuropathy
- Cough
- Proteinuria
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Aggressive behavior
- Anaphylaxis
- Angina
- Angioedema
- Bronchospastic pulmonary disease
- Bundle branch block
- Cardiac arrhythmia
- Cardiomyopathy
- Cerebrovascular accident
- Colitis
- Diabetes mellitus
- Encephalopathy
- Erythema multiforme
- Hearing loss
- Homicidal ideation
- Hypersensitivity drug reaction
- Hypertension
- Hyperthyroidism
- Hypertriglyceridemia
- Hypotension
- Infection
- Interstitial nephritis
- Interstitial pneumonitis
- Kidney disease with reduction in GFR
- Macular retinal edema
- Manic disorder
- Migraine
- Myositis
- Optic neuritis
- Pancreatitis
- Pericarditis
- Pneumonia
- Psoriasis
- Psychiatric disorder
- Pulmonary fibrosis
- Pulmonary hypertension
- Pulmonary infiltrates
- Pure red cell aplasia
- Reactivation of hepatitis B
- Retinal detachment
- Retinal disorder
- Retinal thrombosis
- Rhabdomyolysis
- Rheumatoid arthritis
- Sarcoidosis
- Seizure disorder
- Stevens-johnson syndrome
- Suicidal
- Suicidal ideation
- Systemic lupus erythematosus
- Thrombotic thrombocytopenic purpura
- Thyroiditis
- Toxic epidermal necrolysis
- Urticaria
- Uveitis
- Vision loss
- Vogt-koyanagi-harada disease
Less Severe
- Aphthous stomatitis
- Bronchiolitis
- Dehydration
- General weakness
- Malaise
- Palpitations
- Papilledema
- Tongue discoloration
- Vertigo
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Peginterferon Alfa-2b
Growth inhibition reported in combination with ribavirin. Safety and efficacy not established in pediatrics age < 3 years.
May affect growth rate and weight gain. Monitor for depression and changes in behavior using recommended dose adjustment guidelines.
- 1 Day – 3 Years
- Growth inhibition reported in combination with ribavirin. Safety and efficacy not established in pediatrics age < 3 years.
- May affect growth rate and weight gain. Monitor for depression and changes in behavior using recommended dose adjustment guidelines.
- 3 Years – 18 Years
- Growth inhibition reported in combination with ribavirin. Safety and efficacy not established in pediatrics age < 3 years.
- May affect growth rate and weight gain. Monitor for depression and changes in behavior using recommended dose adjustment guidelines.
Peginterferon Alfa-2B
- Severity Level:
2
- Additional Notes: Insufficient human data; animal data sug dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Peginterferon Alfa-2B
Insufficient data available; large mw; infant oral absorption unlikely
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; large mw; infant oral absorption unlikely |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may rarely cause or worsen some serious medical conditions, including mental/mood problems (such as depression), autoimmune conditions (such as lupus, rheumatoid arthritis), blood vessel problems (such as heart disease), or infections. Careful monitoring by your doctor may decrease your risk. Tell your doctor right away if you develop any serious symptoms or side effects (see Side Effects section).<br /><br />Some side effects may go away or lessen after stopping treatment with this medication. This medication is often used in combination with ribavirin. Ribavirin may cause birth defects and/or death to an unborn baby.<br /><br /> Women must avoid pregnancy while they or their male partners are using ribavirin. Also, ribavirin may cause a blood disorder (hemolytic anemia), which can worsen heart disease. If you are using peginterferon alfa-2b with ribavirin to treat chronic hepatitis C, also carefully read the drug information for ribavirin.
| Chronic hepatitis C - genotype 1 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 2 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 3 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 4 | |
| B18.2 | Chronic viral hepatitis C |
| 0-9 | A-Z |
|---|---|
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
Formulary Reference Tool